Newcastle University Single Cell Unit
Newcastle University Single Cell Unit (NUSCU) is a Medical Research Council (MRC) and university-funded core facility initiative with a mission statement to provide a comprehensive solution to researchers who want to perform single cell analysis at the genomic, transcriptomic and protein level. NUSCU is an integrated facility buttressed by five cores: genomics, flow cytometry, bioimaging, high throughput/automation and bioinformatics that collectively provides cutting-edge instrumentation, expertise and technical support for all researchers within the Medical Faculty and beyond.
CEPA (Cellular Pathology) Biobank
CEPA has REC approval, which allows it access to the extensive Diagnostic Archive of The Newcastle upon Tyne Hospitals NHS Foundation Trust, from which tissue can be released with Pathologist approval if no longer required for diagnostic purposes. CEPA facilitates the supply of tissue, on a cost recovery basis, to support a broad range of research in an ethical manner, including the supply of tissue to commercial companies for quality control and method development purposes. Access to all tissue is overseen by a robust governance structure with well-defined policies and procedures to ensure fair, rapid and transparent access.
Genomics and Genetics
Clinical and laboratory services for genetic diseases are fully integrated in specialist facilities at the Northern Genetics Service. This successful service delivery model is enhanced through close interaction with counterparts in other regional centres at a national level as well as good communication between genetic services and other relevant clinical specialties locally. Clinicians working in the service use multiple diagnostic approaches to help patients understand their condition and make key decisions about their healthcare and the potential implications for their relatives. Underpinning these services is a strong translational research theme conducted in collaboration with researchers in Newcastle University, particularly the Institute of Genetic Medicine and with the staff of the Faculty of Medical Sciences Genomics Core Facility (GCF). The GCF is a state of the art laboratory experienced in service delivery for the academic, clinical and commercial sectors and resourced to operate at production scale, providing data for pilot projects through to large investment discovery research programmes.
Laboratory Medicine in The Newcastle upon Tyne Hospitals NHS Foundation Trust is the largest clinical laboratory service in Europe and is based over two hospital sites – the Royal Victoria Infirmary (RVI) and the Freeman Hospital – and carries out over 11 million tests each year.
The Newcastle upon Tyne Hospitals NHS Foundation Trust has a significant reputation for high quality clinical services and care (described as “Outstanding” by the Care and Quality Commission) and is a world class centre for research and innovation. Newcastle Laboratories undertake laboratory testing for NHS hospitals regionally and nationally, but also provide laboratory services to a wide range of non-NHS organisations including occupational health departments in local government, police forces and academic organisations as well as independent social research agencies, Premiership football clubs, healthcare waste specialists and research laboratories.
All Laboratories hold full accreditation status with UKAS against ISO15189:2012, and are dedicated to providing a high quality, cost effective service across the Trust, as well as general practitioners, community services and other NHS Trusts, both regionally and nationally.
Centre for In Vivo Imaging
The Centre for In Vivo Imaging (CIVI) focuses on three major techniques to image tissue within organs - these include magnetic resonance imaging (MRI), positron emission tomography (PET) and fluorescence techniques (IVIS). These are continually evolving techniques which convey huge flexibility. By combining expertise in the basic science, which underpins the technology, with biomedical drive for application, they can tailor each modality to a myriad of biomedical targets through the innovative development of tracer molecules or new scanning sequences.
Newcastle Molecular Pathology Node
The Medical Research Council and Engineering and Physical Sciences Research Council-funded Newcastle Molecular Pathology Node, one of six centres in the UK, has been established to bring together researchers, clinicians and industry to drive forward advances in precision medicine and develop the next generation of Molecular Pathologist. The innovative ISO-accredited ‘Proximity Laboratory’ enables diverse cohorts to work together in a state of the art, ISO-accredited laboratory within the busy Cellular Pathology Department at the Royal Victoria Infirmary to collaborate on the discovery and adoption of ground-breaking scientific developments. To promote capacity-building in Molecular Pathology a Masters degree and fellowship scheme have been developed with the Trust’s highly skilled team of Consultant Pathologists to ensure the most relevant and up to date practices are disseminated.
NIHR Newcastle Medtech and In vitro Diagnostic Co-operative (MIC)
The newly established NIHR Newcastle Medtech and In vitro Diagnostic Co-operative (NIHR Newcastle MIC) is built upon the success of the previous NIHR Diagnostic Evidence Co-operative (DEC) Newcastle (2013 - 2017). The role of diagnostic tests is to deliver high quality, robust scientific evidence on the care pathway and economic benefits of diagnostic tests — i.e. how their adoption by the NHS would improve patient health and provide value for money in an affordable way.
The NIHR Newcastle MIC will focus upon three areas of important unmet clinical need: ageing and long term chronic conditions, infectious diseases and stratified medicine. This will be supported through collaboration with external partners, such as other NIHR resources, commercial and academic organisations.
The evaluation methodologists working within the NIHR Newcastle MIC are uniquely placed to support commercial and academic technology developers. They have developed strong expertise in clinical, economic and stakeholder engagement research, and collaborate with colleagues in the NHS and Newcastle University when additional expertise and resources are needed. Together, they can plan, design and carry out the necessary research to provide the evidence required by NHS clinicians and commissioners for investing in the most promising new diagnostics, as well as informing key developmental decisions.
NICE External Assessment Centre (EAC)
The EAC is a partnership between The Newcastle upon Tyne Hospitals NHS Foundation Trust and the York Health Economics Consortium (YHEC). They are commissioned by NICE to provide independent assessment of the evidence for innovative medical devices and associated economic analysis of the impact of such technology adoption in the NHS. A multi-disciplinary team, including scientists and health economists at the centre will also liaise with clinical experts, within the Trust and nationally, to work with NICE to progress further research on promising technologies where current evidence is limited.
The evaluation group at the Freeman Hospital has been involved in the national programme of medical device assessment for almost 40 years. Their current role as an External Assessment Centre (EAC) for NICE complements other activities in Medical Physics, including developing innovative medical devices. The partnership with YHEC combines their health economics expertise with our device evaluation and device development knowledge, to offer an all-encompassing EAC to the Medical Technologies Evaluation Programme (MTEP) at NICE, and a comprehensive range of skills in technology assessment to other customers.
The Academic Health Science Network for the North East and North Cumbria
The Academic Health Science Network for the North East and North Cumbria (AHSN NENC) is dedicated to improving healthcare and supporting wealth creation through partnership working and promotion of innovation across the NHS, academia and industry. Through our Innovation Pathway the development and commercialisation of innovative ideas is supported and provides a unique opportunity for SMEs to access and benefit from the healthcare sector.
The Innovation Pathway delivers a brokerage between the NHS, other healthcare organisations and industry, and facilitates the commercialisation and use of emerging innovations, as well as driving high technology research and development. By offering a range of specialist services to the NHS and industry, it will create a seamless transition across the entire Innovation Pathway from conception through to early stage protection of any associated intellectual property, through to the trialling and regulatory approval of new products, and then on to the eventual adoption and dissemination of the innovative technology or service, helping NHS organisations and SMEs in the North East region to grow and expand their target sectors. The Innovation Pathway has the goal of becoming the recognised vehicle for the delivery of innovation in the North East healthcare arena, aiming to improve the economy of the region by creating wealth and job opportunities as well as improving the health and wellbeing of the region as a whole.
NIHR Innovation Observatory (NIHRIO)
NIHRIO is the national medical horizon scanning facility located at Newcastle University. The Innovation Observatory is looking for technologies that are up to 10 years from being publically available, by constantly tracking technologies as they evolve, from patent to patient. The Innovation Observatory has three primary activities; Technology Briefings, advanced horizon scanning tools, and patient involvement.